Knee and Hip Osteoarthritis on Apixaban: How Far Topical Therapy Can Reasonably Go
Topical NSAIDs are strongly favored in older patients, but this patient's pain isn't confined to a joint a gel can reach — and he's on an anticoagulant that raises the stakes of adding anything oral.
T.O., a 74-year-old man, spends most weekend mornings in his garage workshop, a habit that's outlasted both his career at the post office and, lately, his ability to kneel comfortably at the workbench. He built the bench itself the year he retired and still measures his own decline against how long he can stand at it before needing to sit. His right knee has bothered him for a couple of years and has settled into a familiar, moderate ache; his left hip is newer, less clearly defined, and has started catching his attention on stairs in a way that makes him pause at the bottom before starting up. He takes apixaban for paroxysmal atrial fibrillation, diagnosed after an episode of palpitations two years ago, and that single fact sits over every conversation about pain control from here forward. His eGFR of 78 is worth reading rather than filing as normal, because of what it removes from the discussion: the most common reason to withhold an oral NSAID from a 74-year-old is renal, and that reason does not apply to him. Whatever case there is against adding one here is a bleeding argument and only a bleeding argument, which is a narrower objection than it first appears. Acetaminophen alone isn't doing enough for either joint anymore.
The 2019 ACR guideline gives topical NSAIDs its strongest recommendation for knee osteoarthritis, a recommendation strengthened specifically with older patients in mind, precisely because it delivers local drug concentration at the joint without the systemic exposure that matters most when a patient is also anticoagulated. That evidence base is considerably thinner for hip osteoarthritis — there's no way to apply a topical agent directly over a joint that sits as deep as the hip, and the trials behind the topical recommendation were done almost entirely on knees and hands. T.O.'s two joints don't share the same answer to the same question, and his apixaban raises the real stakes of reaching for an oral NSAID to cover whichever joint topical therapy can't reach — a decision that has to be made twice, not once, for one patient in one visit.
One knee that fits the guideline, one hip that doesn't
Topical diclofenac for the knee is the easy part — that's exactly the population and joint the strongest ACR recommendation was built around, and it barely touches his systemic apixaban exposure.
The hip is where I'd stop. His symptoms there are new and, by his own description, still mild. Adding any oral NSAID on top of a direct factor Xa inhibitor for a joint that isn't yet badly symptomatic isn't a trade I'd make yet.
I hear the caution, but he's already changing how he takes stairs because of that hip, and that's not nothing in a man his age — a fall is its own real harm, arguably a bigger one than a manageable NSAID-anticoagulant interaction.
The interaction with apixaban is real, but it's not absolute. A short course of a low-dose oral NSAID, with him aware of what to watch for, is a reasonable trade if his hip pain genuinely isn't controlled by anything else — leaving a real symptomatic joint untreated because the other joint's evidence base happens to be stronger doesn't serve him either.
I don't think we have to choose between undertreating his hip and accepting the interaction for it. The actual gap right now isn't a treatment gap, it's an information gap — we don't have imaging on that hip yet, and it's early enough that a corticosteroid injection there, rather than an oral NSAID, might solve the problem without touching apixaban at all.
Topical diclofenac for the knee now. For the hip: imaging and an orthopedic evaluation for injection candidacy, rather than reaching for an oral NSAID as the default next step just because it's available. If it turns out injection isn't a good option once we actually look, we can have the oral-NSAID conversation again with better information instead of guessing now.
Agreed: topical diclofenac for the right knee, starting now. For the left hip, imaging plus an orthopedic evaluation for corticosteroid injection candidacy before any oral NSAID is considered. Acetaminophen continues in the meantime.
Not agreed: what to do if the hip imaging comes back showing more advanced disease than expected, and injection isn't judged a good option. The rheumatologist would move to a short, carefully monitored oral NSAID course at that point; the geriatrician would prefer exhausting physical therapy and activity modification first, even with a confirmed diagnosis, before touching apixaban's risk profile at all.